A Case Study of the METEMP Protocol: Massed Exposure Therapy Enhanced With 3,4-Methylenedioxymethamphetamine (MDMA) for Posttraumatic Stress Disorder

IF 2.9 3区心理学 Q1 PSYCHOLOGY, CLINICAL

Cognitive and Behavioral Practice Pub Date : 2025-06-03 DOI:10.1016/j.cbpra.2025.02.001

Jessica L. Maples-Keller, Barbara O. Rothbaum

{"title":"A Case Study of the METEMP Protocol: Massed Exposure Therapy Enhanced With 3,4-Methylenedioxymethamphetamine (MDMA) for Posttraumatic Stress Disorder","authors":"Jessica L. Maples-Keller, Barbara O. Rothbaum","doi":"10.1016/j.cbpra.2025.02.001","DOIUrl":null,"url":null,"abstract":"<div><div>This case study provides a detailed description of a participant in an open label clinical trial receiving the METEMP intervention, Massed Exposure Therapy Enhanced with 100 mg 3,4-methylenedioxymethamphetamine (MDMA) for posttraumatic stress disorder. After thorough medical and psychiatric screening to ensure eligibility and appropriateness for this treatment, two clinical psychologists treated a 57-year-old woman with PTSD over a 10-day treatment period. An independent rater not involved in treatment conducted a CAPS-5-R at baseline, 1 week, and 1 month following treatment as the primary outcome. Quantitative results suggest significant PTSD symptom reduction (pretreatment CAPS-5-R = 85, 1-week posttreatment = 1, 1-month posttreatment = 1). PCL-5 and PHQ-9 suggest significant decreases in self-reported PTSD (43 at pretreatment to 1 at 1-month posttreatment) and depression (10 at pretreatment to 0 at 1-month posttreatment). We provide specific details on this novel combined treatment and how PE was modified for MDMA administration. The treatment protocol appears feasible and will continue to be tested in this open label pilot trial before subsequent investigation in a randomized controlled trial.</div></div>","PeriodicalId":51511,"journal":{"name":"Cognitive and Behavioral Practice","volume":"32 3","pages":"Pages 378-392"},"PeriodicalIF":2.9000,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cognitive and Behavioral Practice","FirstCategoryId":"102","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1077722925000045","RegionNum":3,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHOLOGY, CLINICAL","Score":null,"Total":0}

引用次数: 0

Abstract

This case study provides a detailed description of a participant in an open label clinical trial receiving the METEMP intervention, Massed Exposure Therapy Enhanced with 100 mg 3,4-methylenedioxymethamphetamine (MDMA) for posttraumatic stress disorder. After thorough medical and psychiatric screening to ensure eligibility and appropriateness for this treatment, two clinical psychologists treated a 57-year-old woman with PTSD over a 10-day treatment period. An independent rater not involved in treatment conducted a CAPS-5-R at baseline, 1 week, and 1 month following treatment as the primary outcome. Quantitative results suggest significant PTSD symptom reduction (pretreatment CAPS-5-R = 85, 1-week posttreatment = 1, 1-month posttreatment = 1). PCL-5 and PHQ-9 suggest significant decreases in self-reported PTSD (43 at pretreatment to 1 at 1-month posttreatment) and depression (10 at pretreatment to 0 at 1-month posttreatment). We provide specific details on this novel combined treatment and how PE was modified for MDMA administration. The treatment protocol appears feasible and will continue to be tested in this open label pilot trial before subsequent investigation in a randomized controlled trial.

查看原文本刊更多论文

METEMP方案的案例研究：3,4-亚甲基二氧基甲基苯丙胺（MDMA）强化的大规模暴露疗法治疗创伤后应激障碍

本案例研究详细描述了一名接受METEMP干预的开放标签临床试验参与者的情况，即100mg 3,4-亚甲基二氧基甲基苯丙胺（MDMA）强化的大规模暴露疗法治疗创伤后应激障碍。经过彻底的医学和精神病学筛查，以确保这种治疗的资格和适当性，两位临床心理学家对一位患有创伤后应激障碍的57岁女性进行了为期10天的治疗。一名未参与治疗的独立评分者在基线、治疗后1周和1个月进行CAPS-5-R作为主要结局。定量结果显示PTSD症状明显减轻（治疗前CAPS-5-R = 85，治疗后1周= 1，治疗后1个月= 1）。PCL-5和PHQ-9提示自我报告PTSD（治疗前43人，治疗后1个月为1人）和抑郁（治疗后1个月为10人，治疗后1个月为0人）显著降低。我们提供了这种新型联合治疗的具体细节，以及PE如何被修改为MDMA给药。治疗方案似乎是可行的，在随后的随机对照试验调查之前，将继续在这个开放标签试点试验中进行测试。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cognitive and Behavioral Practice PSYCHOLOGY, CLINICAL-

CiteScore

4.80

自引率

3.40%

发文量

118

审稿时长

84 days

期刊介绍： Cognitive and Behavioral Practice is a quarterly international journal that serves an enduring resource for empirically informed methods of clinical practice. Its mission is to bridge the gap between published research and the actual clinical practice of cognitive behavior therapy. Cognitive and Behavioral Practice publishes clinically rich accounts of innovative assessment and diagnostic and therapeutic procedures that are clearly grounded in empirical research. A focus on application and implementation of procedures is maintained.